1. Scrip
  2. >>Business

StemCells names president & COO

 
• By Lucie Ellis-Taitt

Newark, California-based StemCells, a company developing novel cell-based therapeutics for disorders of the central nervous system, has named Ian Massey president and chief operating officer. In this new role, Dr Massey has direct responsibility for all aspects of the company's R&D, manufacturing, regulatory affairs and quality assurance activities. He will report to StemCells' CEO Martin McGlynn. Most recently, Dr Massey was the COO and president of US operations at Biotie Therapies, a publicly traded Finnish company focused on neurodegenerative and psychiatric disorders.

Newark, California-based StemCells, a company developing novel cell-based therapeutics for disorders of the central nervous system, has named Ian Massey president and chief operating officer. In this new role, Dr Massey has direct responsibility for all aspects of the company's R&D, manufacturing, regulatory affairs and quality assurance activities. He will report to StemCells' CEO Martin McGlynn. Most recently, Dr Massey was the COO and president of US operations at Biotie Therapies, a publicly traded Finnish company focused on neurodegenerative and psychiatric disorders.

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Business

Japan Results Roundup: Reduced Forex Impact, Uncertain US Tariff Outlook

 
• By Lisa Takagi

Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 
• By Mary Jo Laffler

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

S&E In Brief: Launch Updates And Political Headwinds

 
• By Sushmita Panda

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.

2030’s Top Therapies: Incretin Agonists Loom Large

 
• By Edwin Elmhirst

Scrip looks at the therapies projected to lead global sales by 2030. These frontrunners not only reflect advances in innovation but also shifting priorities in chronic disease management.

More from Scrip

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By Aakash Babu

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 
• By Alaric DeArment

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.

2030’s Top Therapies: Incretin Agonists Loom Large

 
• By Edwin Elmhirst

Scrip looks at the therapies projected to lead global sales by 2030. These frontrunners not only reflect advances in innovation but also shifting priorities in chronic disease management.